Selective estrogen receptor degraders (SERDs) are a type of anti-hormone therapy used to treat metastatic ER-positive breast cancer. Oral SERDs are taken by mouth instead of given by injection. SERDs attach to the estrogen receptor (ER), prevent ER from working, and eventually lead to ER degradation (the breakdown of estrogen receptors).
Currently, fulvestrant (Faslodex®) is the only SERD approved by the FDA for treating MBC, but fulvestrant is not available in oral form. Many new oral SERDs are being studied in clinical trials for treating MBC that has progressed on tamoxifen or an aromatase inhibitor.
Read below to understand how oral SERDs work and learn about current research, potential future research, and uses of oral SERDs.
What Are Oral SERDs and How Do They Work?
- Breastcancer.org: Estrogen Receptor Downregulators (ERDs)
- Sanofi: Improving ER Antagonism and Degradation can Offer More Potential (video)
- Curr Opin Oncology Research Abstract: Selective Oestrogen Receptor Degraders in Breast Cancer: A Review and Perspectives
- ACS Research Abstract: Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
Current Research and Future Directions of Oral SERDs
- OncLive: Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial
- OncLive: Unlocking the Potential of SERDs in Advanced ER+ Breast Cancer
- SABCS 2020: Brinker Basic Science Award Lecture: Which is Best — SERMs or SERDs — for Treating BCa?
Clinical Trials for Oral SERDs
- Metastatic Trial Search: Trials that Include Oral SERDs